HOLON, Israel, May 11, 2023
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a
clinical-stage cancer immunotherapy company and a pioneer in
computational target discovery, today announced that the
Company will host a virtual DNAM-1 Axis Investor Event on
Tuesday, May 23, 2023 at 12:00 pm ET.
The event will feature Drew
Pardoll, M.D., Ph.D., Professor of Oncology,
Johns Hopkins University, and Chairman
of Compugen's Scientific Advisory Board, who will discuss the
biological mechanistic rationale behind Compugen's differentiated
DNAM-1 axis hypothesis suggesting the simultaneous blockade of
PVRIG, TIGIT and PD-1 has the potential to synergistically enhance
anti-tumor immune responses in selected patient populations who are
not responsive or refractory to PD-1 blockers alone.
A short introductory presentation will be provided by Compugen's
SVP Research and Drug Discovery, Eran
Ophir, Ph.D., followed by a discussant presentation by Dr.
Pardoll.
A live question and answer session with Dr. Pardoll and members
of Compugen's leadership team will follow the formal presentations.
To register for the event, please click here.
About Drew Pardoll, M.D.,
Ph.D.
Dr. Pardoll is the Abeloff Professor of Oncology,
Medicine, Pathology, and Molecular Biology and Genetics at
Johns Hopkins University of Medicine,
and Director of the Bloomberg Kimmel Institute for Cancer
Immunotherapy at the Sidney Kimmel Cancer Center, Johns Hopkins. For the past two decades, Prof.
Pardoll has studied molecular aspects of immune regulation,
particularly related to mechanisms by which cancer cells evade the
immune system and has made seminal advances in immunology,
including the discovery of new types of immune cells and regulatory
mechanisms. He was the first to propose blockade of PD-1 for cancer
therapy, and his research led the clinical development of the first
anti-PD-1 antibody. Prof. Pardoll is the inventor of a number of
immunotherapies, including cancer vaccines, and was a scientific
founder of Amplimmune Inc. Prof. Pardoll completed his M.D., Ph.D.,
Medical Residency and Oncology Fellowship at Johns Hopkins University. Prof. Pardoll acts as a
Scientific Advisory Board Chairman to Compugen.
About Compugen
Compugen is a clinical-stage
therapeutic discovery and development company utilizing its broadly
applicable predictive computational discovery capabilities to
identify new drug targets and biological pathways for developing
cancer immunotherapies. Compugen has developed two proprietary
product candidates: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Compugen also
has a clinical stage partnered program, rilvegostomig (previously
AZD2936), a PD-1/TIGIT bi-specific derived from COM902, in Phase 2
development by AstraZeneca through a license agreement for the
development of bi-specific and multi-specific antibodies. In
addition, the Company's therapeutic pipeline of
early-stage immuno-oncology programs consists of programs
aiming to address various mechanisms of immune resistance. The most
advanced program, COM503 in IND enabling studies. COM503 is a
potential first-in-class, high affinity antibody which blocks the
interaction between IL-18 binding protein and IL-18, thereby
freeing natural IL-18 to inhibit cancer growth in the tumor
microenvironment. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares
are listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN.
Company contact:
Yvonne
Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-host-dnam-1-axis-virtual-investor-event-with-kol-drew-pardoll-on-tuesday-may-23-2023-301821798.html
SOURCE Compugen Ltd.